Disease · MONDO_0015686
Comparisons in its trials113
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 113
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab vs Placebo With Paclitaxel, Carboplatin and Bevacizumab: deaths from any cause | 272 of 651 | 289 of 650 | 1,301 | NCT03038100 | Trial comparisons |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab vs Placebo With Paclitaxel, Carboplatin and Bevacizumab: serious adverse events | 304 of 642 | 215 of 644 | 1,286 | NCT03038100 | Trial comparisons |
| Pazopanib vs Placebo: deaths from any cause | 3 of 477 | 0 of 461 | 938 | NCT00866697 | Trial comparisons |
| Pazopanib vs Placebo: serious adverse events | 121 of 477 | 51 of 461 | 938 | NCT00866697 | Trial comparisons |
| Arm I (Adjuvant Chemotherapy Suboptimally Debulked) vs Arm II (Neoadjuvant Chemotherapy): serious adverse events | 122 of 346 | 167 of 346 | 692 | NCT01167712 | Trial comparisons |
| Pembrolizumab + Paclitaxel ± Bevacizumab vs Placebo + Paclitaxel ± Bevacizumab: deaths from any cause | 225 of 322 | 244 of 321 | 643 | NCT05116189 | Trial comparisons |
| Pembrolizumab + Paclitaxel ± Bevacizumab vs Placebo + Paclitaxel ± Bevacizumab: serious adverse events | 178 of 320 | 122 of 318 | 638 | NCT05116189 | Trial comparisons |
| Trabectedin + DOXIL vs DOXIL: deaths from any cause | 132 of 286 | 131 of 282 | 568 | NCT01846611 | Trial comparisons |
| Trabectedin + DOXIL vs DOXIL: serious adverse events | 118 of 286 | 58 of 282 | 568 | NCT01846611 | Trial comparisons |
| Rucaparib 600 mg Tablets vs Placebo Tablets: deaths from any cause | 9 of 372 | 2 of 189 | 561 | NCT01968213 | Trial comparisons |
| Rucaparib 600 mg Tablets vs Placebo Tablets: serious adverse events | 91 of 372 | 20 of 189 | 561 | NCT01968213 | Trial comparisons |
| Carboplatin and Gemcitabine + Bevacizumab vs Carboplatin and Gemcitabine + Placebo: serious adverse events | 90 of 247 | 59 of 233 | 480 | NCT00434642 | Trial comparisons |
| Mirvetuximab Soravtansine vs Investigator's Choice (IC) Chemotherapy: deaths from any cause | 162 of 227 | 177 of 226 | 453 | NCT04209855 | Trial comparisons |
| Mirvetuximab Soravtansine vs Investigator's Choice (IC) Chemotherapy: serious adverse events | 62 of 227 | 73 of 226 | 453 | NCT04209855 | Trial comparisons |
| Mirvetuximab Soravtansine vs Investigator's Choice (IC) Chemotherapy: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 211 of 218 | 194 of 207 | 425 | NCT04209855 | Trial comparisons |
| Chemotherapy vs Chemotherapy + Bevacizumab: serious adverse events | 49 of 181 | 56 of 179 | 360 | NCT00976911 | Trial comparisons |
| Mirvetuximab Soravtansine vs Investigator's Choice (IC) Chemotherapy: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 242 of 243 | 107 of 109 | 352 | NCT02631876 | Trial comparisons |
| Mirvetuximab Soravtansine vs Investigator's Choice (IC) Chemotherapy: deaths from any cause | 96 of 243 | 50 of 109 | 352 | NCT02631876 | Trial comparisons |
| Mirvetuximab Soravtansine vs Investigator's Choice (IC) Chemotherapy: serious adverse events | 67 of 243 | 31 of 109 | 352 | NCT02631876 | Trial comparisons |
Mirvetuximab Soravtansine vs Investigator's Choice (IC) Chemotherapy: Number of Participants Achieving at Least 15 Point Absolute Improvement in the Abdominal/Gastrointestinal (GI) Scale of European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module 28 (QLQ-OV28) | 34 of 162 | 23 of 150 | 312 | NCT04209855 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015686/comparisons